Lidanserin
Lidanserin (INN; ZK-33,839) is a drug which acts as a combined 5-HT2A and α1-adrenergic receptor antagonist.[1] It was developed as an antihypertensive agent but was never marketed.[1]
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C26H31FN2O4 |
| Molar mass | 454.542 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
References
- Allen RC (1989). Annual Reports in Medicinal Chemistry. Academic Press. p. 56. ISBN 978-0-12-040524-4. Retrieved 6 May 2012.
| Sympatholytics (antagonize α-adrenergic vasoconstriction) | |||||
|---|---|---|---|---|---|
| Other antagonists |
| ||||
| |||||
Adrenergic receptor modulators | |||||
|---|---|---|---|---|---|
| α1 |
| ||||
| α2 |
| ||||
| β |
| ||||
| |||||
Serotonin receptor modulators | |||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5-HT1 |
| ||||||||||||||||||||||||||||||||||||||
| 5-HT2 |
| ||||||||||||||||||||||||||||||||||||||
| 5-HT3–7 |
| ||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.